Hoechst Completes RU Buyout

3 March 1997

- Hoechst has begun a public buyout offer for the remaining 0.73%shares of Roussel Uclaf. It is offering to buy the remaining 180,468 common shares and 18,989 preferred nonvoting shares at a price of 1,530 French francs ($270.80) and 1,330 francs respectively. The public buyout is compulsory because Hoechst already owns 99.8% of the preferred nonvoting shares and 99.3% of the common shares. The buyout will end on March 10, and on March 11, Roussel Uclaf will be delisted from the Paris bourse.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight